Please select the option that best describes you:

Do you consider adding a brachytherapy boost to IMRT in patients with cT3b and/or cN1 prostate cancer?  

ASCENDE-RT excluded these patients as well as those with a PSA > 40, but it seems these patients may stand to benefit as well.



Answer from: Radiation Oncologist at Community Practice
Sign in or Register to read more